🎊 Pharmidex Celebrates the Year of the Snake! 🐍🧧 🎊
January 29, 2025
On January 29, 2025, we welcome the Year of the Snake, a symbol of wisdom, transformation, and resilience. At Pharmidex, we embrace these qualities as we continue to innovate and drive scientific advancements.
May this new year bring prosperity, success, and good fortune to all our colleagues, partners, and friends worldwide. Let’s make 2025 a year of progress, new opportunities, and groundbreaking discoveries!
🌏 Pharmidex |
www.pharmidex.com
The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
